KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Change in Inventory: 2009-2025

Historic Change in Inventory for Neogenomics (NEO) over the last 17 years, with Sep 2025 value amounting to -$5.6 million.

  • Neogenomics' Change in Inventory fell 553.10% to -$5.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.8 million, marking a year-over-year increase of 523.93%. This contributed to the annual value of $2.7 million for FY2024, which is 494.49% up from last year.
  • As of Q3 2025, Neogenomics' Change in Inventory stood at -$5.6 million, which was down 236.60% from $4.1 million recorded in Q2 2025.
  • Over the past 5 years, Neogenomics' Change in Inventory peaked at $4.1 million during Q2 2025, and registered a low of -$5.6 million during Q3 2025.
  • Over the past 3 years, Neogenomics' median Change in Inventory value was $688,000 (recorded in 2023), while the average stood at $424,364.
  • Within the past 5 years, the most significant YoY rise in Neogenomics' Change in Inventory was 1,034.16% (2024), while the steepest drop was 2,018.00% (2024).
  • Neogenomics' Change in Inventory (Quarterly) stood at $1.6 million in 2021, then crashed by 55.38% to $697,000 in 2022, then slumped by 71.02% to $202,000 in 2023, then soared by 1,034.16% to $2.3 million in 2024, then slumped by 553.10% to -$5.6 million in 2025.
  • Its Change in Inventory stands at -$5.6 million for Q3 2025, versus $4.1 million for Q2 2025 and $3.0 million for Q1 2025.